Compare SY & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | RNA |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.7M | 222.5M |
| IPO Year | 2018 | 2025 |
| Metric | SY | RNA |
|---|---|---|
| Price | $2.16 | $12.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $5.50 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 205.3K | 127.8K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.64 | $88.12 |
| Revenue Next Year | $30.63 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $11.13 |
| 52 Week High | $5.35 | $73.06 |
| Indicator | SY | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 51.20 |
| Support Level | $1.68 | $11.95 |
| Resistance Level | $2.15 | $14.05 |
| Average True Range (ATR) | 0.16 | 0.39 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 80.46 | 80.33 |
So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.